-

Thermo Fisher Scientific’s PPD Clinical Research Business Earns Honor for Employee Development Driving Customer Success

WILMINGTON, N.C.--(BUSINESS WIRE)--Thermo Fisher Scientific’s PPD clinical research business has been named a winner in Training magazine’s 2022 Training APEX Awards, recognizing its robust enterprise learning programs designed to grow employees’ skills and drive customers’ success.

As part of Thermo Fisher’s commitment to talent development, the PPD clinical research business designs, develops and deploys a wide range of employee learning and performance programs, providing ongoing training and development that engages employees for optimal performance, leverages technology, develops staff and measures outcomes.

“We are honored to win this award for the 11th consecutive year from the highly regarded team at Training magazine,” said Jay Dixon, senior vice president, quality and enterprise learning, clinical research, Thermo Fisher Scientific. “Our learning programs proactively, measurably and efficiently improve performance, readiness and quality across the organization to best serve our customers and help them achieve their clinical research goals.”

Training magazine’s Training APEX Awards were recently rebranded from the Training Top 100. The awards honor each winner’s journey to attain peak performance in employee training and development and organizational success. The awards assessment team evaluated the scope of each organization’s learning program, including budget, reimbursement, infrastructure, evaluation, human resources and metrics.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Contacts

Media Contact Information:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
Phone: 910-558-4779
Email: nadine.maeser@ppd.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
Thermo Fisher Scientific’s PPD clinical research business has been recognized for its robust enterprise learning programs
Release Versions

Contacts

Media Contact Information:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
Phone: 910-558-4779
Email: nadine.maeser@ppd.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom